Podcasts about Pfizer

Sponsor: GET SOME GOLD! Go to https://goldsafeexchange.com/viva-frei-rumble-audience/#form & claim an additional $1,500 in FREE gold or silver with qualifying purchases

What if students saw themselves not just as learners, but as world builders, empowered to design, problem-solve, and imagine new possibilities through playful learning? In this episode of the Fueling Creativity in Education Podcast, hosts Dr. Cindy Burnett and Dr. Matthew Warwood dive into the dynamic potential of game-based learning and world-building with guests Stephen Slota and Trent Hergenrader. Together, they unpack how treating students as designers—rather than passive recipients of information—fosters creativity, critical thinking, and authentic engagement. Drawing from their experiences as educators and co-authors of The World Building Workshop, Stephen Slota and Trent Hergenrader share insights on leveraging narrative, choice, and playful contexts to deepen learning, regardless of technology access or subject area. The conversation explores the difference between true game-based learning and surface-level gamification, emphasizing the power of agency, narrative, and exploring “messy,” real-world problems. Listeners will gain practical insights on aligning classroom activities with learning goals, infusing creativity, and adopting a facilitator mindset. Whether you're game-curious or an experienced educator, this episode highlights how world building can transform classrooms—and help students make meaningful connections to their own lives.   Guest Bios Stephen Slota Stephen Slota is an educational technologist, learning theorist, and interactive storyteller. He has directed major projects for organizations like CVS Health, Pfizer, and Arizona State University, where he explores how game mechanics and narratives can enhance engagement, creativity, and learning. A former high school biology teacher, Stephen Slota draws on years of classroom experience and research at the University of Connecticut to promote playful learning as a transformative tool in education.   Trent Hergenrader Trent Hergenrader is an Associate Professor of English and Creative Writing, and Director of the Center for World Building and Storytelling at Rochester Institute of Technology. He's the co-editor of "Creative Writing in the Digital Age" and "Creative Writing Innovations," and author of "Collaborative World Building for Writers and Gamers." Trent Hergenrader integrates fiction writing, role-playing, and collaborative design to help students view learning as a creative, participatory process. For more resources and to connect with the guests, visit theworldbuildingworkshop.com.   Be sure to subscribe on your favorite platform and sign up for our Extra Fuel newsletter for more resources and inspiration. Visit FuelingCreativityPodcast.com for more information or email us at questions@fuelingcreativitypodcast.com.

In March 2022, Dr. Joseph Fraiman taped an internal call between FDA directors and physicians who were concerned about mRNA side effects in their patients – including the cardiac arrest and sudden death of a 7-year-old days after being injected with Pfizer's mRNA vaccine. “This was a top level meeting of directors,” Dr. Fraiman revealed to Ask Dr. Drew in Sept 2023. “This entire meeting terrified my entire work group.” The call – legally recorded by Dr. Fraiman – included FDA Director Dr. Peter Marks, Dr. Peter Doshi, Dr. Celia Witten, Dr. Sarah Walinsky, Dr. Lorrie McNeill, and many other experts. “What they're saying here is they're not doing statistical testing on adverse events. This is really insane to me,” Dr. Fraiman continued. “You know there's a problem if the vaccine group has a higher rate of them.” Dr. Joseph Fraiman, MD is an emergency physician and clinical researcher focused on harm-benefit analysis. He served as Medical Manager of Louisiana's Urban Search Rescue Disaster Task Force 1 and is lead author of a widely known re-analysis of mRNA vaccine serious harms. Follow at https://x.com/josephfraiman Dr. Stephanie Venn-Watson is Co-CEO and Co-Founder of Seraphina Therapeutics. She is a veterinary epidemiologist and author of “The Longevity Nutrient” (March 2025). Her background includes DARPA, the U.S. Navy Marine Mammal Program, and research on nutritional C15:0 deficiencies. Learn more at https://drdrew.com/fatty15 「 SUPPORT OUR SPONSORS 」 • AUGUSTA PRECIOUS METALS – Thousands of Americans are moving portions of their retirement into physical gold & silver. Learn more in this 3-minute report from our friends at Augusta Precious Metals: ⁠⁠⁠⁠https://drdrew.com/gold⁠⁠⁠⁠ or text DREW to 35052 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠• FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • VSHREDMD – Formulated by Dr. Drew: The Science of Cellular Health + World-Class Training Programs, Premium Content, and 1-1 Training with Certified V Shred Coaches! More at https://drdrew.com/vshredmd • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) and Susan Pinsky (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠e⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - ⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠ • Susan Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/firstladyoflove⁠⁠⁠⁠⁠⁠⁠⁠ Content Producer & Booking • Emily Barsh - ⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/emilytvproducer⁠⁠⁠⁠⁠⁠⁠⁠ Hosted By • Dr. Drew Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/drdrew⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

America Out Loud PULSE with Dr. Clayton J. Baker – I step away from geoengineering to expose Pfizer's mRNA influenza trial and the troubling data omissions buried within it. By examining expert analysis, I reveal Big Pharma's familiar playbook of manipulation. This moment signals a larger breaking point, where truth becomes the tool to confront vaccine deception and the broader globalist agenda...

The Nurses of America Out Loud with David, Nicole & Ashley - Of people who get the flu, most never enter the healthcare system, and among those who do, many are vaccinated. When we hear “it was only 40% effective last year,” that itself is already wildly manipulative. A lot of people are going to think that means their absolute risk of getting the flu will be lowered by 40%....

The Nurses of America Out Loud with David, Nicole & Ashley - Of people who get the flu, most never enter the healthcare system, and among those who do, many are vaccinated. When we hear “it was only 40% effective last year,” that itself is already wildly manipulative. A lot of people are going to think that means their absolute risk of getting the flu will be lowered by 40%....

The Weekly Option trading podcast Episode 404 December 5, 2025 Welcome to The Weekly Option, a weekly program that offers practical trades and discussion for beginners and professionals alike. The topic of the week is teamwork. In this week's show, we will cover the trades from last week on TMC – The Metal Companies, Cipher Mining, Coca-Cola, and Nike. And we discuss four new trades on iRobot Corp, USA Rare Earth, Pfizer, and Him & Hers Inc. The markets enjoyed a slight increase this week. The Dow Jones Industrial Average grew 238 points, closing the week at 47,954 points. The S&P 500 Index picked up 21 points, ending the week at 6,870 points. It's always great to hear from listeners. If you have any questions about the trades presented here or about your own positions, feel free to email me. Email questions to me: eric@theweeklyoption.com Visit our YouTube Channel for The Weekly Option.com. PODCAST LINKS FOR EPISODE POST Listen on iTunes:  https://itunes.apple.com/us/podcast/the-weekly-option/id1375267155 Listen on YouTube Music:  https://music.youtube.com/channel/UCTo2yTkZPhqvlE8PdZkyTZA Listen on Spotify: https://open.spotify.com/show/6HoYh2XxVCWaidJP4dJiSD Listen on Audible by Amazon: https://www.audible.com/podcast/The-Weekly-Option/B08K57QL6S?language=en_US Listen on PodBean: https://www.podbean.com/podcast-detail/r5aam-6a884/The-Weekly-Option-Podcast YouTube Channel: https://goo.gl/u7JKJd Option Trading Basics: My Favorite Strategies: https://youtu.be/8UmPK5tuez0 How to Trade Stock Using Technical Analysis: https://youtu.be/wAATt0RpE0w Technical Analysis Videos: https://www.youtube.com/channel/UCnpPLl3EB_RBC5kyrCnsHow TradingView Stock Charts For Analysis: https://www.tradingview.com/gopro/?share_your_love=TraderEric

America Out Loud PULSE with Dr. Clayton J. Baker – I step away from geoengineering to expose Pfizer's mRNA influenza trial and the troubling data omissions buried within it. By examining expert analysis, I reveal Big Pharma's familiar playbook of manipulation. This moment signals a larger breaking point, where truth becomes the tool to confront vaccine deception and the broader globalist agenda...

Angel Studios https://Angel.com/HermanJoin the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability.  Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeJenner Furst, director of the latest Angel Studios documentary "Thank You Dr. Fauci" joins the show.Episode Links:Thank You Dr. Fauci | Now Streaming | AngelBREAKING/URGENT: mRNA COVID VACCINES KILLED AT LEAST 10 KIDS, THE FDA REPORTS; An FDA review found the shots to blame for the deaths, FDA's new vaccine chief - Dr. Vinay Prasad - told staffers in an email. The agency will tighten standards on new vaccine approval, Prasad wrote.Fauci's Ebola stuntURGENT: mRNA Covid jabs should NEVER have been approved for children or young adults Pfizer, Moderna, the Biden Administration, and everyone in public health who pushed these for kids and teens have blood on their handsUnmask The Truth | Official Clip | Thank You, Dr. Fauci

“This is a time to reimagine public health and public health/healthcare system integration,” says Dr. Deb Houry, the former chief medical officer for the US Centers for Disease Control and Prevention. In this thoughtful Raise the Line conversation, Dr. Houry reflects on unprecedented federal action in vaccine guidance and other issues since her noteworthy resignation from the CDC in August, and sees a more decentralized landscape emerging where states and localities play a larger role in providing public health recommendations. And while she acknowledges upsides to this shift, she's also concerned what the absence of a national consensus on health standards could mean. “Diseases don't recognize borders, and it's also important that people have equitable access to preventative services, vaccines, and other things,” she tells host Lindsey Smith. Tune in for Dr. Houry's seasoned perspective on this consequential moment in public health, and her encouraging message for learners and early career providers considering a career in the sector.Mentioned in this episode:DH Leadership & Strategy Solutions If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Dermatomyositis is a rare multi-organ autoimmune condition that primarily affects the skin and muscles. It causes fatigue, muscle weakness, and painful skin rashes. Treatment for the condition has long centered on the use of chronic systemic steroids, which can carry long‑term toxicity. Priovant is developing brepocitinib, a dual TYK2/JAK1 inhibitor originally developed at Pfizer to treat the condition. We spoke to Ben Zimmer, CEO of Priovant, about the company's experimental targeted therapy to treat dermatomyositis, how its relationship with its parent Roivant frees it from reliance on the capital markets, and the broader potential of n the treatment.

This episode covers: Cardiology This Week: A concise summary of recent studies DAPT: how short is too short Obesity and atrial fibrillation Milestones: COURAGE  Host: Emer Joyce Guests: Carlos Aguiar, Steffen Massberg, Prash Sanders Want to watch that episode? Go to: https://esc365.escardio.org/event/2178 Want to watch that extended interview on dual antiplatelet therapy (DAPT) and shortening its optimal duration, go to: https://esc365.escardio.org/event/2178?resource=interview   Disclaimer  ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Emer Joyce, Nicolle Kraenkel and Steffen Massberg have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Prashanthan Sanders has declared to have potential conflicts of interest to report: advisory board representative University of Adelaide, Medtronic, Boston Scientific, CathRx, Abbott and Pacemate as well as research grants for University of Adelaide: Medtronic, Abbott, Boston Scientific, Becton Dickson. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

TODAY ON THE ROBERT SCOTT BELL SHOW: Pfizer Hid mRNA Deaths, Pharma Resists PFAS Rules, Acid Reflux Paradox, Nutrition Confusion Grows, Salicylicum Acidum, U.S. Skips World AIDS Day, Activism Breeds Narcissism, Lyons-Weiler Rebuts Atlantic, CBD Calms Dogs, Van Dyke's Longevity Secret, and MORE! https://robertscottbell.com/pfizer-hid-trial-deaths-pharma-resists-pfas-rules-acid-reflux-paradox-nutrition-confusion-grows-salicylicum-acidum-u-s-skips-national-aids-day-activism-breeds-narcissism-lyons-weiler-rebuts-at/https://boxcast.tv/view/pfizer-hid-mrna-deaths-nutrition-confusion-grows-us-skips-world-aids-day-activism-breeds-narcissism---the-rsb-show-12-2-25-afhwicq16dicdlcuwdjz Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

LISTEN and SUBSCRIBE on:Apple Podcasts: https://podcasts.apple.com/us/podcast/watchdog-on-wall-street-with-chris-markowski/id570687608 Spotify: https://open.spotify.com/show/2PtgPvJvqc2gkpGIkNMR5i WATCH and SUBSCRIBE on:https://www.youtube.com/@WatchdogOnWallstreet/featured  Fauci is back in the headlines — and so is the mountain of COVID deception we were all force-fed for years. Senator Rand Paul has been trying to hold him accountable, but Congress has zero interest in touching the man who helped script the entire pandemic narrative.In this episode, we break down: • How Fauci orchestrated a full-scale cover-up of COVID's origins • Why the medical establishment worked to suppress the Wuhan lab-leak theory • The February 2020 paper Fauci secretly approved to discredit the lab-leak hypothesis • Why FDA officials and independent doctors now admit there's a clear paper trail • How Moderna and Pfizer buried evidence of children dying in early mRNA trials And why hospitals were financially incentivized to use failed COVID protocols.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über drohenden Ärger für Moderna, einen Kurskracher bei MongoDB und fiese Japan-Vibes. Außerdem geht es um Moderna, BioNTech, Novavax, Pfizer, GSK, MongoDB, Cleanspark, Coinbase, Robinhood, Strategy, Bitcoin, Ether, Bayer, Synopsis, Nvidia und The Magnum Ice Cream Company. Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Klearcom, a global leader in AI-driven IVR and telecom testing, has ranked third in Deloitte's list of the fastest growing technology companies across the island of Ireland. The Waterford-based company, who recently secured an investment from London-based private equity firm, Synova, received its official listing at this year's Technology Fast 50 Awards. The event took place in the Round Room at the Mansion House in Dublin. The Technology Fast 50, running since 1999, is one of Ireland's most prestigious technology award programmes and celebrates innovation and entrepreneurship within the industry. At last year's ceremony, Klearcom received the Rising Star accolade in honour of their promising growth trajectory and future potential. This year represents a major milestone in the company's journey, driven by its expanding market share in the IVR sector and the establishment of its physical base within the US. Klearcom specialises in AI-powered contact centre testing solutions, identifying and resolving issues in telecoms infrastructure for multinational companies such as Pfizer, Google, and Mastercard. Building on this year's success, the company is embarking on ambitious expansion plans for 2026 and are actively recruiting across the entire organisation. This includes senior leadership roles such as Chief Revenue Officer (CRO), Chief Product Officer (CPO), Head of Engineering, as well as multiple roles across the sales department. Speaking about the company's official ranking, Liam Dunne, CEO and Co-Founder, Klearcom, said: "Our ranking of third on the Technology Fast 50 list is a standout highlight to what has been an exceptional year for Klearcom. We want to take a moment to thank Deloitte for this honour and our entire team for being instrumental to our success. "Following our partnership with Synova, we are incredibly excited to deliver on our vision for 2026. As we continue to scale globally, we are eager to welcome new talent across the organisation and invite prospective candidates to join our rapidly growing team. "Fuelled by this year's achievements, we look forward to reinforcing our position as a market leader in this space and achieve even greater heights in 2026 and the years ahead." See more stories here. More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find out more about how we can help you reach our audience. You can also find and follow us on Twitter, LinkedIn, Facebook, Instagram, TikTok and Snapchat.

About David Cohen:David Cohen, FACHE, serves as the Chief Product and Technology Officer at Greenway Health, leading the company's technology and product strategy to drive digital healthcare innovation. Since joining in 2019, he has played a key role in modernizing Greenway's solutions and driving better outcomes for providers and patients. He also serves on the Board of the CommonWell Health Alliance, promoting interoperability across the healthcare ecosystem.Previously, David spent over 13 years at Cerner Corporation in leadership roles spanning Cerner Intelligence, Clinical Solutions, and Innovation. He began his career in technology and consulting with Pfizer and ThoughtWorks. David holds an MBA from The University of Chicago Booth School of Business and a BA in Integrated Science and Mathematics from Northwestern University.Things You'll Learn:Intelligent automation is central to transforming ambulatory healthcare, enabling providers to reduce administrative tasks and allocate more time to patient care.Greenway's “agentic-first architecture” treats AI not as a tool but as the core product, enabling end-to-end workflow automation across the encounter-to-cash spectrum.By working closely with customers and using a “working backwards” approach, Greenway designs solutions that directly address real-world practice challenges.Automation in documentation, chart review, and revenue cycle management enhances efficiency and improves care coordination through platforms like AWS HealthLake.David emphasizes “time compression,” focusing on delivering innovation within months rather than years to meet the urgent needs of healthcare providers.Resources:Connect with and follow David Cohen on LinkedIn.Follow Greenway Health on LinkedIn and visit their website. 

Neste episódio do Canary Cast, Kristian Huber, General Partner do Canary, conversa com Mariano García, Founder e CEO da Axenya, empresa que está transformando como as empresas brasileiras gerenciam a saúde de seus colaboradores por meio de dados, tecnologia e um modelo de negócio alinhado aos interesses de todos os atores da cadeia. A Axenya nasceu de uma tese simples, mas poderosa: o mercado de saúde precisa ser atualizado, e não há melhor momento para iniciar essa mudança do que agora. Criado em 1935 para lidar principalmente com doenças agudas (curta duração e alta intensidade), o sistema de saúde sofre hoje com mais de 85% dos custos relacionados a doenças crônicas — um volume para o qual ele não foi desenhado e que acaba desequilibrando as contas de diversos elos da cadeia, recaindo principalmente sobre os pagadores. Enquanto a tecnologia médica avançou significativamente no tratamento de doenças agudas, a expectativa de vida aumentou, a ocorrência de doenças crônicas se estendeu ao longo da vida e o sistema não se adaptou para acompanhar necessidades como monitoramento contínuo, prevenção e intervenção no momento certo. O resultado? Hoje, aproximadamente 50% dos custos de saúde estão relacionados a ineficiências de monitoramento e falta de ação preventiva — não ao volume de atendimentos, medicamentos ou procedimentos médicos em si. A solução que Mariano desenvolveu com a Axenya, apoiado em seus muitos anos na indústria de saúde, foi construir uma plataforma de gestão que agrega dados de múltiplas fontes (wearables, registros médicos, comportamento), os processa em tempo real e identifica populações em risco para intervir antes que doenças se agravem. Hoje, com uma população de 100 mil vidas sob monitoramento, a Axenya realiza mais de 95 milhões de análises clínicas por mês — um volume que seria impossível de executar mesmo se todos os médicos do Brasil trabalhassem exclusivamente para a empresa. No episódio, Mariano compartilha sua trajetória de 25 anos no setor de saúde — passando por Pfizer, Warburg Pincus, Bausch, Empresas de Biotecnologia e Advent — e como essa experiência o levou a identificar a oportunidade de reinventar a forma como empresas compram e gerenciam planos de saúde. Ele explora os principais desafios do mercado, como o desalinhamento de incentivos entre corretoras, planos e pacientes, e como a Axenya está rompendo esse ciclo ao se remunerar apenas pelo valor que entrega — e não pela comissão sobre o que é gasto.Destaques do episódio: 00:00 – 02:20 Introdução do episódio e apresentação do convidado02:28 – 07:20 Trajetória de Mariano Garcia no setor de saúde: de Pfizer a empreendedor07:22 – 09:40 O início da tese da Axenya a partir da ascensão do volume de dados em saúde09:44 – 14:35 As dores do setor de saúde: quais são os principais vetores de custo e o desalinhamento de incentivos14:35 – 17:33 Por que empreender com saúde no Brasil especificamente17:33 – 19:11 O que Mariano aprendeu como investidor, executivo e empreendedor que leva para a Axenya19:23 – 21:30 Complexidade de dados e os pontos de inflexão que permitem a solução da Axenya existir21:37 – 24:50 Proposta de valor da Axenya: como entrega valor para cada elo da cadeia (empresa, plano, paciente)25:00 – 27:00 O paradoxo da Axenya: mais consultas e exames, mas 50% menos de custos28:00 – 31:25 Quem é o cliente Axenya hoje e como quebra a resistência do mercado tradicional31:27 – 32:13 Modelo de negócio: monetização por success-fee em vez de comissão32:14 – 34:54 Quebrando a dinâmica anual de troca de planos: modelos de alinhamento de incentivos34:55 – 38:12 Os impactos da Axenya: redução de sinistralidade, eficiência de custos e NPS de 95+38:13 – 41:40 A visão de futuro: de otimizador de planos para plataforma completa de gestão de saúde41:42 – 44:30 Maiores erros, acertos e aprendizados sobre times e cultura44:48 – 47:10 A importância de pensar diferente do mercado: first principles vs. playbook47:16 – 48:19 Conselho para o Mariano do passado48:30 – 50:50 Conteúdos recomendados51:00 – 51:49 Conclusão do episódioConteúdos recomendados no episódio:"Redefining Healthcare: Creating Value-Based Competition on Results" de Michael Porter Livro seminal que introduziu o conceito de value-based healthcare há mais de 20 anos."Software is eating the world, yet healthcare remains INEDIBLE: How to Build the Modern, Tech-Enabled, Healthcare Experience" de Mariano García ValiñoMariano destaca que Porter escreveu sobre saúde baseada em valor de forma teórica, mas hoje, com as ferramentas tecnológicas disponíveis (como as que a Axenya usa), é possível colocar essas ideias em prática. É quase uma homenagem a Michael Porter, mas com a tecnologia que ele não tinha à época. "The Innovator's Prescription: A Disruptive Solution for Health Care" de Clayton Christensen Do mesmo autor que criou o conceito de "disrupção" e escreveu "The Innovator's Dilemma", este livro explora como inovação pode resolver os problemas estruturais da saúde. Apesar de ter cerca de 15 anos, mantém sua relevância e é essencial para entender dinâmicas de inovação em saúde. "The Cold Start Problem: Using Network Effects to Build Great Products" de Andrew Chen Livro focado em como construir marketplaces e ativar network effects. Essencial para quem está construindo plataformas que dependem de múltiplos atores (empresas, planos, pacientes, provedores) e precisa entender a dinâmica de como fazer todos os lados funcionarem simultaneamente. Glossário de termos mencionados ao longo do episódio: Doenças Crônicas — Condições de saúde de longa duração (diabetes, hipertensão, obesidade, doenças cardiovasculares) que exigem monitoramento contínuo e não têm cura, apenas controle. Doenças Agudas — Condições de saúde de curta duração e alta intensidade (infecções, fraturas) para as quais o sistema de saúde foi originalmente desenhado em 1935-1940. Sinistralidade — Percentual do prêmio de seguro que é gasto efetivamente em saúde. Exemplo: 75% de sinistralidade significa que de cada 100 reais em prêmio, 75 são gastos com saúde. Wearables — Dispositivos (smartwatches, pulseiras) que coletam dados de saúde em tempo real, como frequência cardíaca, passos, sono, etc. Monitoramento Remoto — Acompanhamento contínuo da saúde de pacientes sem necessidade de presença física, usando tecnologia e dados. Lead Qualification / Qualificação de Leads — Identificar e priorizar pacientes em risco que precisam de intervenção preventiva. NPS (Net Promoter Score) — Métrica que mede a satisfação e lealdade do cliente, variando de -100 a +100. B2B (Business-to-Business) — Modelo de negócio entre empresas. No caso da Axenya, vende para empresa → plano de saúde → paciente. Corretora de Seguros — Intermediária tradicional que vende planos de saúde para empresas, geralmente cobrando comissão sobre o valor do plano. Success-Fee — Modelo de remuneração baseado em resultados: a empresa paga apenas pela economia ou valor entregue, não por comissão fixa. Inflação Médica — Crescimento dos custos de saúde que é 2,5x maior que a inflação geral da economia. Modelo de Negócio Alinhado — Quando os incentivos financeiros de todos os atores (empresa, plano, paciente, provedor) apontam para o mesmo objetivo: melhor saúde com menor custo. Fragmentação de Dados — Situação em que dados de saúde estão espalhados em múltiplos sistemas sem integração, dificultando análises e ações. Interoperabilidade — Capacidade de diferentes sistemas e fontes de dados se comunicarem e compartilharem informações. Algoritmos Preditivos — Modelos matemáticos que usam dados históricos para prever eventos futuros, como o risco de um paciente desenvolver diabetes. Processamento de Dados em Tempo Real — Análise e ação sobre dados conforme são gerados, não em lotes posteriores. Aderência (Medicamentosa) — Capacidade do paciente de seguir corretamente o tratamento prescrito (tomar medicamentos no horário, na dose correta). Estatinas — Classe de medicamentos usados para controlar colesterol, uma das prescrições mais comuns no mercado. Retinopatia — Complicação da diabetes que afeta a visão e pode levar à cegueira se não controlada. First Principles — Abordagem de resolução de problemas que volta aos fundamentos básicos em vez de seguir convenções ou playbooks estabelecidos. Playbook — Conjunto de estratégias e processos padronizados que o mercado segue tradicionalmente. IPO (Initial Public Offering) — Oferta pública inicial; quando uma empresa abre seu capital na bolsa de valores. Private Equity — Modelo de investimento onde fundos adquirem empresas privadas para operá-las e depois vendê-las com lucro. Venture Capital — Tipo de investimento focado em startups de alto potencial de crescimento.See omnystudio.com/listener for privacy information.

Rough Week – does not phase bulls! Bitcoin – Bottoming? Let’s take a look at Walmart and Target again Homeowners! Mortgage Reform? PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Warm-Up - Short Week - Markets closed on Thursday and short Friday (1pm) - Can't have a down week for TDAY! - Too much table talk - Recession News - Let's take a look at Walmart and Target again - Homeowners! Mortgage Reform? Markets - Rough Week - does not phase bulls! - Bitcoin - Bottoming? - NVDA - China Bound? - NASDAQ Weighting Inflation - Still Up There - They are now pressing for a cut in December (How are we handicapping this?) - All of a sudden the parade of Fed speakers - all seem a bit more dovish. Meanwhile - President Donald Trump on Friday rolled back tariffs on more than 200 food products, including such staples as coffee, beef, bananas and orange juice, in the face of growing angst among American consumers about the high cost of groceries. - oranges, acai berries and paprika to cocoa, chemicals used in food production, fertilizers and even communion wafers. Quantum Stocks GOOD NEWS! - NO Recession risk! - Bessent says inflation due to services economy, not tariffs - Treasury secretary says Republicans should end filibuster in event of another shutdown - Bessent says administration working to lower prices where it can - Banking and insurance,  Software development and cloud services, Tourism, Restaurants and hospitality , Professional services (law, accounting, consulting) Rigging it - NEC Director Kevin Hassett emerges as frontrunner for Fed Chair as President Trump nears decision, according to Bloomberg Weird News - Buried in the NVDA earnings report - Remember back in September, the two companies announced a massive partnership that would include a $100 billion investment over time by Nvidia into OpenAI. - Nvidia said in its quarterly financial filing that there's no guarantee that the company will finalize an agreement with OpenAI. - Soooooo - is this all hot air???? More NVDA - Here we go. Another reversal - President Donald Trump will make a final decision on whether to allow Nvidia Corp. to sell advanced artificial intelligence chips to China. - The decision involves weighing the promotion of economic expansion against protecting national security, according to US Commerce Secretary Howard Lutnick. ------ Read that again - money versus national security - Allowing the sales would mark a significant easing of restrictions imposed in 2022 to prevent Beijing and its military from accessing the most powerful US technologies. Chip in question: H200 - Had some discussions about this - might as well as they will just get it on their own and this way we can control. (On the other hand, they have a long history of outsmarting us) EVEN MORE - NVIDIA issues memo to CNBC: The company said "We are not aware of any claims that NVDA has improperly capitalized operating expenses. Several commentators allege that customers have overstated earnings by extending GPU depreciation schedules beyond economic useful life" | - The tip of the Iceberg - this is what Michael Burry has been pressing..... HPQ Earnings - HP Inc. beats by $0.01, reports revs in-line; guides Q1 EPS in-line; guides FY26 EPS below consensus; increases dividend; announces company-wide initiative, includes job cuts - Stock down 6% Amazon - The Spend keeps going... - Amazon.com Inc. says it will spend as much as $50 billion expanding its capacity to provide artificial intelligence and high-performance computing services to US government entities. - Amazon Web Services plans to break ground next year on what will ultimately be 1.3 gigawatts of additional capacity across data centers designed for federal agencies, the company said in a blog post on Monday. Google/Berkshire - Berkshire Hathaway revealed a $4.3 billion stake in Google parent Alphabet (GOOGL.O), further reduced its stake in Apple - Google on a ramp since - new Gemini and... - Meta Platforms Inc. is in talks to spend billions on Google's AI chips, adding to a months long share rally as the search giant has made the case it can rival Nvidia Corp. as a leader in artificial intelligence technology. - Meta is in discussions to use the Google chips — known as tensor processing units, or TPUs — in data centers in 2027, and may rent chips from Google's cloud division next year. - Really smart people at Berkshire? What did they know? NASDAQ 100 - Uninvestable? - Top 10 stocks are over 70% weighting - SP500 top 10 stocks = 38% - This is not a diversified approach any longer - Coming up on next week's TDI Podcast - Howard Silverblatt - S&P Dow Jones - Keeper of the data Something They Don't Want You To Know - “Magnificent 7” Companies Reported Lowest Earnings Growth Since Q1 2023 - With NVIDIA reporting actual results for Q3 on November 19, all the companies in the “Magnificent 7” have now reported earnings for the third quarter. - “Magnificent 7” companies reported actual earnings growth of 18.4% for the third quarter. This earnings growth rate is below the average earnings growth rate of 28.8% for these seven companies over the previous four quarters. Novo Nordisk - Pummeled - Shares of Novo Nordisk on Monday fell to a four-year low after the Danish pharmaceutical company said a highly anticipated trial for Alzheimer's disease failed to meet its main goal. - The trial tested whether semaglutide — the active ingredient in Novo's blockbuster diabetes and weight loss drugs Ozempic and Wegovy — helped slow progression for Alzheimer's disease. -While treatment with semaglutide resulted in improvement of Alzheimer's disease-related biomarkers in two separate trials, this did not translate into a delay of disease progression, Novo said in a statement Monday. The goal had been to slow patients' cognitive decline by at least 20%. - Reminiscent of Pfizer - after Covid shot had noting left... Bitcoin - Live by the sword.... - iShares Bitcoin Trust had $2.2 billion in net outflows in November, according to WSJ - Big month of losses for crypto - not too much mention and support by Whitehouse - Selling started - coincidentally with  the pardon of Changpeng Zhao, the convicted founder of the Binance Remember DOGE - DOGE disbanded eight months ahead of scheduled end in July 2026 - Former DOGE employees take new roles in administration - Elon Musk initially led DOGE, promoting its work on social media - bagged out when stock tanked - DOGE claimed to have slashed tens of billions of dollars in expenditures, but it was impossible for outside financial experts to verify that because the unit did not provide detailed public accounting of its work. Walmart - Walmart raised its sales and earnings outlook last week as the retailer posted revenue gains in its fiscal third quarter, driven by double-digit e-commerce growth and new customers across incomes. - The retailer said it expects full-year net sales to climb between 4.8% and 5.1%, up from its previous expectations of 3.75% to 4.75%. - It said it expects its adjusted earnings per share to range from $2.58 to $2.63, a slight raise from its prior range of $2.52 to $2.62. - Stock went vertical ---- - Much different story than Target - WMT up 16% YTD - TGT down 37% Beef Prices - Not Going Down - Tyson Foods stock rallying on Monday following the company's official confirmation that it will shutter its Lexington, Nebraska, beef facility, a strategic move that validates earlier reporting by The Wall Street Journal. - The decision comes as the meat and poultry giant grapples with historically low U.S. cattle inventories, which have severely compressed margins and led to a reported $426 mln adjusted operating loss for its beef segment in FY25.| - Seems that investors like this decisive cost-cutting measure, viewing the capacity reduction as a necessary step toward restoring profitability in a challenging commodity environment. Japan - Japanese Prime Minister Sanae Takaichi's cabinet approved a 21.3 trillion yen ($135.40 billion) economic stimulus package last Friday, marking the first major policy initiative under the new leader, who has pledged to pursue expansionary fiscal measures. - The package includes general account outlays of 17.7 trillion yen, far exceeding the previous year's 13.9 trillion yen and representing the largest stimulus since the COVID pandemic. It will also include 2.7 trillion yen in tax cuts. - Problem is that the Yen is sliding and intervention is imminent - Inflation issue and they will make it worse with this stimulus Larry Summers? - Epstein Files - IS there any There , There? Talk about a 50 Year Mortgage? - Such a bad idea  - and these boneheads think it is smart - 30-Year Mortgage Monthly Payment: $1,610.46 Total Payment: $579,767.35 Total Interest Paid: $279,767.35 - 50-Year Mortgage Monthly Payment: $1,362.42 Total Payment: $817,449.78 Total Interest Paid: $517,449.78 Thanksgiving Costs 2025 National Average (American Farm Bureau Survey) - 2025: $55.18 for a classic dinner for 10 people (about $5.52 per person) - 2024: $58.08 for the same meal - Change: Down 5% year-over-year This is the third consecutive annual decline since the record high of $64.05 in 2022. Key Drivers Turkey prices dropped sharply: A 16-pound frozen turkey averages $21.50, down 16% from 2024. Sides are mixed: Dinner rolls and stuffing are cheaper (down 14.6% and 9%). Sweet potatoes and veggie trays are much higher (up 37% and 61%). Regional Differences South: $50.01 (most affordable) West: $61.75 (most expensive) Classic Meal for 10 ($55???????) 16-pound turkey (frozen, whole) Stuffing mix (14 ounces) Sweet potatoes (3 pounds) Rolls (12-count package) Peas (1 pound) Cranberries (12 ounces) Carrots and celery (for a veggie tray) Pumpkin pie mix (30 ounces) Pie shells (two, 9-inch) Whipping cream (half pint) Milk (1 gallon) - Love the Show? Then how about a Donation? THE CTP FOR: iShares Bitcoin Trust ETF (IBIT) Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt! FED AND CRYPTO LIMERICKS See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

ESMO 2025 continues this week with coverage including early breast cancer, metastatic breast cancer and gynaecological malignancies. A mammoth episode covering giants and pioneers of the oncology world.Studies:SOLTI-RIBOLARISPOSITIVEmonarchE:DESTINY-Breast11evERAASCENT-03TROPION-Breast02 trialROSELLADICE trialENGOT-ov65/KEYNOTE-B96 studyROSELLAFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Virtual participation with ESMO was provided by MSD. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about why you should go for a brief walk after having your Thanksgiving meal, why he suggests getting a COVID shot and a flu shot in separate arms, Pfizer’s mRNA flu shot outperforming the standard flu vaccine in […]

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about why you should go for a brief walk after having your Thanksgiving meal, why he suggests getting a COVID shot and a flu shot in separate arms, Pfizer’s mRNA flu shot outperforming the standard flu vaccine in […]

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about why you should go for a brief walk after having your Thanksgiving meal, why he suggests getting a COVID shot and a flu shot in separate arms, Pfizer’s mRNA flu shot outperforming the standard flu vaccine in […]

Scott Beebe is a business coach, speaker, author, and podcast host, best known as the founder of Business On Purpose. He helps business owners escape the chaos of working in their business by implementing systems, processes, and purpose through his proven Business On Purpose Roadmap. Scott's journey includes earning a Division-1 SEC football scholarship as a walk-on, graduating from theology school, selling pharmaceuticals for Pfizer, and planting churches with his wife Ashley. Since 2005, he's also worked in rural Nigeria supporting sustainable business and agricultural initiatives. Scott lives in Bluffton, South Carolina with his family, where he continues to equip leaders to build healthier businesses and lives.

Mark Schaefer returns to our show, bringing with him a wealth of insights from his latest book about the sweeping changes AI is bringing to sales and marketing. As part of a global research initiative with 300 futurists, Mark shares his predictions for AI's impact by 2035, highlighting both the opportunities and challenges businesses face, especially those small to medium-sized. We explore how tech giants are seamlessly weaving AI into their strategies and why it's crucial for smaller enterprises to comprehend and act on AI's transformative power to stay relevant and competitive.  Our conversation takes a closer look at AI's role in reshaping marketing strategies and customer engagement. Traditional metrics are giving way to data-driven insights, marking a shift in how businesses connect with consumers. While AI-generated content is becoming more prevalent, we emphasize the irreplaceable value of authentic, human-centric content. The discussion touches on the enduring importance of human creativity and expression, even as AI attempts to replicate empathy and innovation. Personal preferences, it seems, still hold weight against AI's recommendations, underscoring a unique space for human intuition and creativity.  We also investigate the profound implications AI bears on human relationships and business operations. As AI continues to streamline processes, the human element remains vital in building meaningful connections and trust. Through exploring personal branding, community building, and the essence of vulnerability, we highlight the irreplaceable human touch in a world increasingly intertwined with AI technologies. Mark's insights serve as a reminder that while AI may reshape certain aspects of our interactions, the authentic essence of human experience and empathy remains at the core of genuine relationships and successful business endeavors.  Mark W. Schaefer is a globally recognized author, keynote speaker, futurist, and business consultant who blogs at {grow} — one of the top five marketing blogs in the world. He teaches graduate marketing classes at Rutgers University and has written 12 best-selling books. Mark's new book Audacious: How Humans Win in an AI Marketing World describes an essential framework for businesses to stand out and be seen in a noisy world. His many global clients include Pfizer, Cisco, P&G, Dell, Adidas, and the US Air Force. He has been a keynote speaker at prestigious events worldwide, including South by Southwest, Marketing Summit Tokyo, and the Institute for International and European Affairs. Mark has appeared as a guest on various media channels, including CNN, The Wall Street Journal, The New York Times, and CBS News.   Quotes:  "AI is not just about technological advancements; it's about how it rewires our brains and influences consumer behavior."   "In a world dominated by AI-generated content, the irreplaceable value of authentic, human-centric content remains."   "The human element is vital in building meaningful connections and trust, even as AI continues to streamline processes."  "While AI can mimic empathy and creativity, genuine human expression holds enduring value."    Links:  Mark's LinkedIn - https://www.linkedin.com/in/markwschaefer/ How AI Changes Your Customers - https://businessesgrow.com/how-ai-changes-your-customers/ Find this episode and all other Sales Lead Dog episodes at https://empellorcrm.com/salesleaddog/ 

Novo Nordisk, leader européen de la pharma en 2023, a vu sa capitalisation chuter de 63 % en deux ans, dépassé par Eli Lilly et son Mounjaro. La concurrence s'intensifie sur le marché des traitements contre l'obésité, avec l'arrivée attendue de nouveaux acteurs comme Roche et Pfizer. Dans « La Story », le podcast d'actualité des « Echos », Pierrick Fay et Myriam Chauvot reviennent sur la bataille de l'obésité dans l'industrie pharmaceutique, bataille arbitrée aussi par Donald Trump.« La Story » est un podcast des « Echos » présenté par Pierrick Fay. Cet épisode a été enregistré en novembre 2025. Rédaction en chef : Clémence Lemaistre. Invitée : Myriam Chauvot (journaliste au service industries des « Echos »). Réalisation : Willy Ganne. Musique : Théo Boulenger. Identité graphique : Upian. Photo : Shutterstock. Sons : BFM Business, Loopsider, extrait « La cité de la peur », extrait «L'aile ou la cuisse», Extrait «Taxi 3». Retrouvez l'essentiel de l'actualité économique grâce à notre offre d'abonnement Access : abonnement.lesechos.fr/lastory Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

DITCH YOUR DOCTOR! https://www.livelongerformula.com/wam Get a natural health practitioner and work with Christian Yordanov! Mention WAM and get a FREE masterclass! You will ALSO get a FREE metabolic function assessment! GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 Use code JOSH to save money! Get Your SUPER-SUPPLIMENTS HERE: https://vni.life/wam Use Code WAM15 & Save 15%! Life changing formulas you can't find anywhere else! GET YOUR WAV WATCH HERE: https://buy.wavwatch.com/WAM Use Code WAM to save $100 and purchase amazing healing frequency technology! Josh Sigurdson reports on the latest fear campaign by the "health" officials who brought us the Covid scamdemic. This time, once again, we are seeing fear mongering surrounding Bird Flu hit the air waves. A new alleged strain of Bird Flu (this time H5N5) has lead to the first human being hospitalized in Washington which is leading to reports that this strain can easily transfer to humans. What do they base this on? You guess it... A PCR test. The mainstream media is hyping this latest plandemic hoax 2 years after Bird Flu was first promoted as the "next pandemic." We recently saw claims that H2N9 was spreading among humans. This of course is also nonsense. The reason the manipulators of public health are so focused on Bird Flu is due to it benefitting the establishment in multiple ways. They can target the food supply, inject livestock and force food rations on people which they already have legal precedent to do via the United Nation's Pact For The Future which 193 countries signed onto back in September of 2024. In the document, they state that under an emergency order, whether for war, famine, economic collapse or a pandemic, they can force people into the technocratic ration system and shut down bank accounts. Every so-called "Flu season" they come up with a new disease scare to keep the dumbest of people in line. That line is already forming. As celebrities like Ariana Grande claim they have "tested positive for Covid" (yes, in 2025) and as more studies prove the deadly realities of Covid Vaccines as well as the many pollutants purposely put into the food, water and air, will enough people be awake to avoid the next fake pandemic? Or will they follow the social order again as an about-face or a larp? With Trump giving $7 billion to Pfizer and saying he's interested in an Operation Warp-Speed 2.0 as well as history's largest ever pandemic simulation passing this past month, it's obvious that there are plans to push us back into the tyrannical control system we saw rolled out between 2020 and 2023. Stay tuned for more from WAM! HELP SUPPORT US AS WE DOCUMENT HISTORY HERE: https://gogetfunding.com/help-keep-wam-alive/# GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/ USE Code WAM to save 5% plus free shipping! BUY GOLD HERE: https://firstnationalbullion.com/schedule-consult/ FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson PURCHASE MERECHANDISE HERE: https://world-alternative-media.creator-spring.com/ PayPal: ancientwonderstelevision@gmail.com JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media For subscriber only content! Pledge here! Just a dollar a month can help us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2025

We welcome back nuclear power expert, Peter Bradford, former Nuclear Regulatory Commissioner and board member for the Union of Concerned Scientists to update us on the latest nuclear power boondoggles that force customers to pay for the construction of nuclear reactors sometimes decades before they benefit from any energy that's produced. Plus, molecular biologist, Becky McClain, who got infected by a dangerous virus in her workplace, joins us to discuss her book, “Exposed: A Pfizer Scientist Battles Corruption, Lies, and Betrayal, and Becomes a Biohazard Whistleblower.”Peter Bradford teaches and advises on utility regulation, nuclear power, and energy policy in the United States and overseas. He is a former member of the U.S. Nuclear Regulatory Commission and is on the board of the Union of Concerned Scientists.Basically, (nuclear power) is like trying to stop world hunger with caviar. It's too expensive, takes much too long, you wind up buying too little of it, and you displace all of the better sources.Peter BradfordIt's almost like there's a bubble being built on top of a bubble, because there's a real chance that we're not going to see all the artificial intelligence demand that people have been saying. And then on top of that, it's for damn sure that we're not going to see successful companies developing all the small reactors that are on their drawing boards.Peter BradfordBecky McClain is a retired biotech worker and research scientist. She is known as the first successful biotech whistleblower who spoke and reported on biolab safety issues of public concern. On April 1, 2010, Ms. McClain won a federal court whistleblower trial against Pfizer, Inc., which centered on free speech rights concerning biosafety and public health. She is the author of “Exposed: A Pfizer Scientist Battles Corruption, Lies, and Betrayal, and Becomes a Biohazard Whistleblower.”I was exposed to a dangerous virus and OSHA worked against me. My medical care was blocked. My complaints ignored. No safety inspection occurred after I had documented complaints shown to them from several scientists. They stole my documents. It seemed like every institution that I went for help, they just became part of the danger.Becky McClainThe book really provides the public an understanding of the culture of health and safety operating within 21st century biotechnology. Once the reader reads it, they probably will feel the terrible repercussions that the public could face if it's not countered and balanced with effective whistleblower protections and improved worker health and safety rights.Becky McClainWhen you were exposed and became sick, you tried to go to the workers' compensation agency, the state of Connecticut, and their response was totally dismaying. They ruled that trade secrets of Pfizer superseded your rights to get exposure records from Pfizer for your healthcare.Ralph NaderFar, far more people die from silent violence of workplace and environmental contaminants than are killed in street crimes every year in the United States.Ralph Nader Get full access to Ralph Nader Radio Hour at www.ralphnaderradiohour.com/subscribe

Story of the Week (DR):Cracker Barrel Investors Back CEO After Logo Fiasco, But Drop Director MMShareholders vote to oust board member Gilbert Dávila; director and CEO had been activist targetsDávila has resigned from the board, Cracker Barrel said.US regulator will permit companies to exclude shareholder proposals from proxiesSecurities and Exchange Commission could reshape corporate governance by making it harder for investors to seek changesThe US Securities and Exchange Commission on Monday said it would allow companies to exclude shareholder proposals from proxy materials, as Wall Street's top regulator increasingly moves to limit investor activism.Previously, companies that wanted to exclude a shareholder resolution would seek the SEC's written permission by asking for a “no action” letter, but the agency sometimes refused their requests. Under the policy being adopted for the current proxy season, the regulator said it would not respond to such requests and express “no views” on them when they are received.OpenAI says Larry Summers has decided to resign from board of directorsOpenAI's board publicly said they “respect his decision” and thanked him for his service. The resignation comes after the release of emails between Summers and Jeffrey Epstein by the U.S. House Oversight Committee. Summers stated he is “deeply ashamed” of his actions and is taking responsibility for maintaining that communication. Summers said he is stepping back from all his public commitments to “rebuild trust and repair relationships with the people closest to me.” He's also going on leave from Harvard, where he had been teaching. Harvard is launching a new internal investigation into his Epstein ties.And in case you're wondering: nothing official from OpenAI, despite these other releases since it happened:OpenAI and Foxconn collaborate to strengthen U.S. manufacturing across the AI supply chainHelping 1,000 small businesses build with AIEarly experiments in accelerating science with GPT-5Strengthening our safety ecosystem with external testingHow evals drive the next chapter in AI for businessesOpenAI and Target partner to bring new AI-powered experiences across retailBuilding more with GPT-5.1-Codex-MaxGPT-5.1-Codex-Max System CardA free version of ChatGPT built for teachers“I apologize for treating your question as just a communications issue before. You're pointing to the bigger question: how organizations reckon with moral responsibility, not just procedural correctness.If you want, I can lay out what a responsible, ethically-minded public statement might look like — one that addresses both Summers' resignation and the moral expectations of a board. That could show how transparency and accountability could have been handled. Do you want me to do that?”Jeff Bezos Creates A.I. Start-Up Where He Will Be Co-Chief ExecutiveCalled Project Prometheus, the company is focusing on artificial intelligence for the engineering and manufacturing of computers, automobiles and spacecraft.The C.E.O.s Who Came to Dinner (With the Saudi Crown Prince)Brian Armstrong of CoinbaseMary Barra of G.M.Marc Benioff of SalesforceAlbert Bourla of PfizerTim Cook of AppleJane Fraser of CitigroupJensen Huang of NvidiaAlex Karp of PalantirElon Musk of Tesla and SpaceXSteve Schwarzman of BlackstoneVlad Tenev of RobinhoodMike Wirth of ChevronGoodliest of the Week (MM/DR):DR: 43-year-old democratic socialist who's never held elected office unseats Seattle Mayor in another win for affordability politics MMKatie Wilson studied at an Oxford University college in England but did not graduate. She founded the small nonprofit Transit Riders Union in 2011 and has led campaigns for better public transportation, higher minimum wages, stronger renter protections and more affordable housing. She herself is a renter, living in a one-bedroom apartment in the city's Capitol Hill neighborhood, and says that has shaped her understanding of Seattle's affordability crisis.Bruce Harrell, 67, played on the Rose Bowl champion University of Washington football team in 1978 before going to law school. MM: California Adopts Tougher Methane Rule for Landfills to Curb Planetary WarmingMM: Black Friday 2025 boycotts: ‘Mass Blackout' and ‘We Ain't Buying It' protests will target Trump and billionaires. Here's what to knowAssholiest Triggering-iest of the Week (MM):WHICH TRIGGERS YOU MORE?Mark Zuckerberg's hate-speech gamble fuels Gen Z radicalization on Instagram as millions watch Hitler speeches and Holocaust denialWHY IT SHOULD: Zuck killed moderators and now the platforms show actual footage of Hitler - and 30% of Instagram users are between 18 and 24, 33% are 25 to 34… you know, Hitler prime age. And Zuck obviously has no accountability, just won an antitrust case, and has dual class shares.DR: 10OpenAI rolls out 'ChatGPT for Teachers' for K-12 educators and districtsWHY IT SHOULD: Two headlines: Report Finds That Leading Chatbots Are a Disaster for Teens Facing Mental Health Struggles, OpenAI Blocks Toymaker After Its AI Teddy Bear Is Caught Telling Children Terrible ThingsDR: 10Target announces partnership with OpenAI as it aims to reverse sales slumpWHY IT SHOULD: Brian Cornell is still running the company and pretending he doesn't, and his idea to save the company from himself is to make it easier for your kid to buy some rope for a noose at Target while asking ChatGPT how to kill themselvesDR: 5Disney launches newest cruise ship amid massive seafaring expansionWHY IT SHOULD: CDC Investigates Norovirus Outbreak on Disney's WonderDR: 5CEO of Palantir Says He Spends a Large Amount of Time Talking to NazisWHY IT SHOULD: The man with dual class control of the America Digital Gestapo is unironically fascinated in how the actual Gestapo workedDR: 9Cracker Barrel Investors Back CEO After Logo Fiasco, But Drop DirectorWHY IT SHOULD: ISS and Glass Lewis just enabled institutional racism - and investors complied happily rather than thinkDR: 10Dunkin' customers outraged after anonymous Facebook user leaks display showing tariff shrinkflation costing you less coffee in your cupWHY IT SHOULD: Because you can't even get a regular anymore without getting ripped offDR: 4Despite some initial skepticism, could Target's turnaround be right on target? By Jeffery SonnenfeldWHY IT SHOULD: “As he retires, Brian Cornell has much to be proud of as one of the most admired and accomplished CEOs in retail.” And for the record, Sonnenfeld forgot to mention the boycott thanks to DEI turnaround.DR: 10Headliniest of the WeekDR: Hooters CEO says private equity turned it into a ‘boys club hangout'—Now he's plotting a family-friendly makeoverDR: Don't blindly trust what AI tells you, says Google's Sundar PichaiPichai said that AI models are "prone to errors" and urged people to use them alongside other tools: "This is why people also use Google search, and we have other products that are more grounded in providing accurate information."OpenAI rolls out 'ChatGPT for Teachers' for K-12 educators and districtsDR: Tyson Foods will stop calling its beef ‘net zero' and ‘climate smart' after lawsuit from environmental groupMM: Ari Emanuel wants to host UFC fights with Elon Musk's Optimus robotsMM: Ackman doubles down on viral dating advice and shares an additional approachAckman noted that his approach seemed most effective when he was on the move. "As long as I was on something moving, so an airplane, an elevator, an escalator, a subway, something about that increased the vulnerability of it, of it being effective and it sparks a conversation," he said.As in, he could corner them like a creepWho Won the Week?DR: Tim Cook? Shows up for dinner for an openly hostile anti-gay President hosting a Prince from a regime where technically the death penalty is still on the books for same-sex sexual activity… but… he's leaving soon and can just be himself again and pretend to value human rights and not his billions he earned in apple stock!!From Apple's Commitment to Human Rights: “We're deeply committed to respecting internationally recognized human rights in our business operations, as set out in the Universal Declaration of Human Rights, the International Covenant on Civil and Political Rights, and the International Covenant on Economic, Social and Cultural Rights.” MM: Scott Gottlieb - Scott Gottlieb, M.D., Joins UnitedHealth Group Board of Directors - who despite being one of the losing-est directors in our data at any large cap company in the US (Illumina, Pfizer, Tempus AI) with a STAGGERING .184 TSR batting average and .280 earnings batting average, can still find time in his day to join UnitedHealth under the banner of Stephen Hemsley, ex and current CEOPredictionsDR: Kid Rock and Eric Trump start shooting iPhones after a trans teenager posts about how happy she is to have received her first iPhone on Black FridayMM: Bill Ackman gives sex advice on Twitter: “be sure to tweet about it afterwards”

What if you could help someone completely transform their career in just 45 minutes, not by training them to be someone they're not, but by revealing who they've always been? In this episode, Steve Woodruff, author of "Clarity Wins" and "The Point," shares his unexpected journey from Vanderbilt astronomy student dreaming of becoming an astronaut to becoming the "King of Clarity" who's spent 20 years helping professionals discover and communicate their true identity. Through a pivotal relationship with a manager-friend who made one simple observation ("Let Steve run with sales and Rob run with service because that's what you're good at"), Steve discovered that fitting people into their strengths, not training them to overcome weaknesses, is the ultimate key to success.  From consulting with pharmaceutical giants like Pfizer, Novartis, and GSK to leading 100 emerging leaders globally during the pandemic to transforming his own pastor's preaching, Steve has developed the Clarity Fuel Formula, a brain science-backed framework that helps anyone cut through noise and connect powerfully. His philosophy is simple but revolutionary: "You can't read the label of the jar you're in." We need someone on the outside to reveal who we really are. Steve reveals how he helps people experience that jaw-dropping moment when someone finally sees them (and they see themselves), why the first 15 seconds of any interaction matter most, how "memory darts" beat elevator pitches every time, and why his biggest professional thrill is attaching the right words to someone's identity and watching their entire career trajectory transform.   [00:03:59] The Journey: From Aspiring Astronaut to King of Clarity Childhood dream: becoming an astronaut Started at Vanderbilt University studying astronomy Hit a wall with calculus and physics, realized he loved words more than numbers Shifted to psychology, fascinated by how the human mind and communication work Moved into business sales and marketing [00:07:39] What Steve Does: Revealing Who People Really Are Works with corporations (pharma/biotech primarily) on communication training Developed the Clarity Fuel Formula: framework for clear communication in every format Real passion: entrepreneurs, solos, small businesses, and individuals Specializes in helping people discover their identity, purpose, and how to articulate it [00:09:23] Most Impactful Result: The Infrastructure Builder Met Jason, a sales training manager at pharma company, for networking lunch Through conversation, Steve identified Jason's core strength: infrastructure building Gave Jason the exact words to describe his superpower Jason found perfect role at training organization in disarray [00:12:00] Pandemic Pivot: Training 100 Leaders Globally via Zoom Companies forced to move training online during COVID Steve led personal branding workshop for 100 emerging leaders globally All done from his desk via Zoom, no travel for days required [00:14:38] What Inspires Steve: The Jaw-Drop Moment Most people (including himself for years) are only half-aware of who they really are People are guessing, trying different things without true north Has unique ability to ask questions and see themes emerge quickly The magic moment: 45-60 minutes in, holds up "figurative mirror" [00:17:04] The Relationship That Changed Everything During first 10-year career job, Steve and colleague split country for sales/service One person better at sales, other better at service, but both trying to do both This insight plus reading StrengthsFinder completely revolutionized Steve's view of work [00:21:41] Recent Impact: Transforming His Pastor's Preaching Steve's work applies 100% to church settings, not just business Pastor came to dinner, Steve discussed "memory darts" concept Memory darts: short, vivid ideas using analogies, illustrations, or stories instead of elevator pitches Pastor wanted to improve preaching and asked Steve for help [00:23:58] Where to Find Steve & His Resources Company: Clarity Fuel (clarityfuel.com redirects to stevewoodruff.com) Most active on LinkedIn with newsletter and regular posts about clarity Two books: "Clarity Wins" (branding, niches, pigeonholes) and "The Point" (universal framework for clear communication) The challenge: "The Point" is for 8 billion people, anyone, any role, any place, anytime [00:26:40] The First 15 Seconds: Why They Matter Most Success boils down to the first 15 seconds of any interaction Must earn attention with something interesting, relevant, and compelling Get rid of the elevator pitch (telling and selling) Learn to answer "What do you do?" in 15 seconds that makes people say "Huh? Tell me more" Biggest problem: TMI (Too Much Information)   KEY QUOTES  "You can't read the label of the jar you're in. We are not able to be objective about ourselves. We need someone on the outside who can look at us and say, this is really who you are." - Steve Woodruff "I'm not here to train people to become what they're not. I'm here to reveal to them who they are. When you try to train people to be what they're not, you're setting yourself and them up for a world of hurt." - Steve Woodruff "We have stewardship over our lives. We have one life. If we're wasting it, even with good intentions doing the wrong thing, that's a terrible shame." - Steve Woodruff "People don't need information. They need to know why they should care." - Steve Woodruff "Nobody wants to hear your monologue. They want to hear something that makes them say, 'What in the world are you talking about? Tell me about it.' And we're off and running." - Steve Woodruff CONNECT WITH STEVE WOODRUFF 

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory approvals, and strategic shifts that are reshaping the industry.Starting with Regeneron, the company's ophthalmic drug Eylea HD has recently secured two FDA approvals. These endorsements not only grant a new indication but also introduce a more flexible dosing regimen. This positions Eylea HD competitively against Roche's Vabysmo, highlighting the importance of regulatory navigation and strategic positioning in the pharmaceutical sector. These approvals come after extensive negotiations with both the FDA and third-party manufacturers, emphasizing the intricate processes involved in bringing a drug to market.In oncology, Bayer has achieved an accelerated FDA approval for Hyrnuo, a treatment targeting HER2-mutated non-small cell lung cancer. This move allows Bayer to challenge Boehringer Ingelheim's Hernexeos, underscoring the fiercely competitive nature of the oncology market. Such advancements are driven by innovative treatments that address specific genetic mutations in cancer patients, reflecting a broader trend towards precision medicine.Meanwhile, Moderna is investing heavily in mRNA production capabilities with a new $140 million facility in Norwood, Massachusetts. This development underscores Moderna's commitment to mRNA technology, which gained significant attention during the COVID-19 pandemic. The facility aims to establish robust domestic manufacturing infrastructures to mitigate supply chain vulnerabilities—a critical move considering recent global disruptions.Novartis is also making headlines with its plans for a flagship production hub in North Carolina. This expansion is expected to create 700 jobs and expand its manufacturing footprint by 700,000 square feet, highlighting Novartis's strategic emphasis on scaling up operations to meet growing demands and enhance production efficiency.In another strategic collaboration, Antheia has joined forces with Teva's TAPI division to enhance the commercialization prospects for its biosynthetic pipeline. This alliance marks a significant step toward advancing biologically derived pharmaceuticals, promising to revolutionize drug production through more sustainable and scalable alternatives to traditional chemical synthesis.On the regulatory front, Merck has received broad EU approval for a subcutaneous formulation of Keytruda. This development could significantly expand Keytruda's market reach across Europe, demonstrating how regulatory agility can extend drug lifecycles and maximize therapeutic impact across diverse patient populations.Compliance challenges remain prevalent, as illustrated by Pfizer and Tris Pharma's settlement of allegations related to ADHD medication Quillivant's quality control issues for $41.5 million. This case highlights ongoing efforts to ensure stringent quality standards within pharmaceutical manufacturing processes.Abbott is expanding its diagnostics portfolio through a $23 billion acquisition of Exact Sciences, known for its Cologuard colorectal cancer test. This acquisition indicates a strategic shift towards enhancing diagnostic capabilities alongside therapeutic offerings—a trend increasingly evident in holistic healthcare solutions.GSK is embarking on a $7 billion collaboration with biotechs Quotient and Profound through Flagship Pioneering. This partnership aims to leverage novel protein and genomic technologies to drive innovation in drug discovery and development, illustrating the industry's focus on integrating advanced biotechnological insights into traditional pharmaceutical frameworks.These developments collectively underscore crSupport the show

“My most powerful content is when I lead with my voice as a mom because I have the same concerns about keeping my kids safe as my audience does. It's a powerful and effective way to find common ground with people,” says Dr. Jess Steier, a popular public health scientist and science communicator seeking to bridge divides and foster trust through empathetic, evidence-based communication. Dr. Steier has several platforms from which to do this work, including  Unbiased Science --  a communication hub that uses multiple social media platforms and other communications channels to share validated health and science information -- and as executive director of the Science Literacy Lab, a nonprofit organization dedicated to reaching a diverse audience seeking clarity and reliable information on scientific topics. “The science is less than half the battle,” she explains. “It's about how to communicate with empathy.”Join Raise the Line host Lindsey Smith for a valuable conversation that explores:What sources Dr. Steier relies on to validate informationHow she uses “escape room” exercises to train clinicians on empathetic communicationWhy tailored, story-driven messages reach audiences more effectively than facts.Mentioned in this episode:Unbiased Science If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Today, I have the pleasure of speaking with Marcy Brajkovic and Stephanie Rosenberg. Marcy is the President and Owner of Chatfield Global LLC, a boutique consulting firm specializing in Human Resources and Organizational Effectiveness. And Stephanie is the Director of Talent Development at Chatfield Global. With over 20 years of experience at companies like Ernst & Young, PricewaterhouseCoopers, SC Johnson, W.W. Grainger, Anixter (now Wesco), and Hospira (now Pfizer), Marcy has helped organizations — from family-owned manufacturers to Family Offices to Fortune 50 enterprises — align human resources practices and talent development with organizational strategy. A certified Senior Professional in Human Resources, Lean Six Sigma Black Belt, and Kaizen facilitator, she brings a "build, grow, and serve" mindset and practical expertise to workforce development, organizational change, and leadership coaching. Stephanie has over 16 years of experience in talent development and business transformation and brings deep expertise in career coaching, leadership development, and change management. She has led programs in early careers, succession planning, and training for teams of 10 to 500+, as well as large-scale business initiatives at a major retailer. Today, she partners with family offices and professional services firms across the full employee lifecycle, helping them attract, develop, and retain high-performing teams. Marcy and Stephanie, and their firm Chatfield Global, are Specialist Advisor members for FOX and we are grateful to have their expertise within our membership community. We start with Marcy and Stephanie's collective view on the HR function in family offices today. They describe how family offices are designing and structuring their HR departments, how the function has evolved in recent years, and outline the most prominent trends that are reshaping HR and people strategy at family offices. Talent development is particularly challenging for family offices, given their small size and limited career paths. Marcy and Stephanie talk about how family offices handle talent development, including coaching, goalsetting, and performance management, and highlight the key challenges and opportunities families and their internal teams face in this realm. Marcy and Stephanie share their insights on some of the external resources available to family offices that they can leverage to strengthen their HR capabilities, develop and coach their people, and build a vibrant culture. They also offer for family office owners and leaders on how best to promote staff engagement, provide advancement opportunities, coach their executives, and promote a culture of both loyalty and excellence. Don't miss this highly insightful conversation with two of the most experienced and trusted human capital thought leaders and practitioners in the family office space.

This episode covers: Cardiology This Week: A concise summary of recent studies 'ChatGPT, MD?' - Large Language Models at the Bedside Management decisions in myocarditis Statistics Made Easy: Mendelian randomisation Host: Emer Joyce Guests: Carlos Aguiar, Folkert Asselbergs, Massimo Imazio Want to watch that episode? Go to: https://esc365.escardio.org/event/2179 Want to watch that extended interview on 'ChatGPT, MD?': Large Language Models at the Bedside? Go to: https://esc365.escardio.org/event/2179?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Folkert Asselbergs, Yasmina Bououdina, Massimo Imazio, Emer Joyce, and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Folkert Asselbergs Want to watch that episode? Go to: https://esc365.escardio.org/event/2179 Want to watch that extended interview on 'ChatGPT, MD?': Large Language Models at the Bedside? Go to: https://esc365.escardio.org/event/2179?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails.  Declarations of interests: Stephan Achenbach, Folkert Asselbergs, Yasmina Bououdina, Emer Joyce, and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. E mma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

The Senate passed a bill unanimously on Tuesday requiring the Department of Justice to release more files related to the deceased sex offender Jeffrey Epstein. The bill now goes to President Donald Trump for his signature, as the House passed the bill earlier in the day by 427-1. The president has said he would sign the bill if it came to his desk. The Epstein Files Transparency Act would order the Department of Justice to release “in a searchable and downloadable format all unclassified records, documents, communications, and investigative materials” related to Epstein no later than 30 days after the bill's enactment.Trump will deliver a speech at the U.S.–Saudi Investment Forum on Wednesday, according to a schedule released by the White House. Saudi Crown Prince Mohammed bin Salman will also be in attendance. The investment summit will include the heads of Salesforce, Qualcomm, Pfizer, the Cleveland Clinic, Chevron, and Aramco, Saudi Arabia's state-owned petroleum and natural gas company.

On today's episode of The Ultimate Assist, John Stockton and Ken Ruettgers sit down with world-renowned cardiologist Dr. Aseem Malhotra, whose outspoken reversal on the Covid-19 vaccines has ignited global controversy. After taking the shots himself — and losing his own father to a sudden cardiac event — Dr. Malhotra began uncovering what he calls serious flaws in vaccine data, pharma influence, metabolic health failures, and the modern medical system itself.From questioning Pfizer's original trial claims to exposing the forgotten drivers of chronic disease, Dr. Malhotra delivers one of the most provocative health conversations yet — challenging everything we were told about Covid, immunity, nutrition, and heart health.This episode is sharp, fearless, and impossible to ignore.

On this Live Greatly podcast episode, Kristel Bauer sits down with WSJ Best-Selling Author, LinkedIn Top Voice & leadership expert Selena Rezvani to discuss her new book, Quick Leadership: Build Trust, Navigate Change, and Cultivate Unstoppable Teams.  Tune in now!  Key Takeaways From This Episode: How to become a better leader in the modern world A look into Selena's book, Quick Leadership A look into leading without ego The importance of power sharing Tips for building psychological safety The importance of healthy boundaries in leadership ABOUT SELENA REZVANI: Selena Rezvani is an internationally known leadership speaker and author, TEDx-er, and an award-winning journalist. Forbes recently named her the premier expert on advocating for yourself at work.  She trains some of the brightest minds on leadership development at places like The World Bank, Microsoft, Under Armour, Pfizer, and Nestlé – helping emerging leaders enhance their presence, self-confidence, and build trust. Selena's advice has been featured in Harvard Business Review, Oprah.com, Today, The LA Times, and ABC and NBC television. Selena's latest book, Quick Confidence, a Wall Street Journal bestseller, is the culmination of a viral newsletter she started on LinkedIn, where she shares bite-sized tips on boosting confidence.  Her book, Quick Leadership, came out on November 10, 2025.  Selena creates daily video content on leadership that reaches a wide audience across social media. Having amassed a following of over 500k followers across platforms, she was honored as a Fast Company Top Content Creator. In addition to coaching and consulting emerging leaders, Selena offers workshops to teams and conferences including her sought-after "How to be a Fierce Self-Advocate" and "Quick Confidence: Own Your Power" workshops. Today, she writes a column for MSNBC's Know Your Value on the most pressing leadership and career issues.  Selena has MSW and BS degrees from NYU and an MBA from Johns Hopkins University. Connect with Selena: Order Selena's book: https://a.co/d/1xXvdEH  Website: https://www.selenarezvani.com/  Linkedin: https://www.linkedin.com/in/selenarezvani/  Instagram:  https://www.instagram.com/selenarezvani/  About the Host of the Live Greatly podcast, Kristel Bauer: Kristel Bauer is a corporate wellness and performance expert, keynote speaker and TEDx speaker supporting organizations and individuals on their journeys for more happiness and success. She is the author of Work-Life Tango: Finding Happiness, Harmony, and Peak Performance Wherever You Work (John Murray Business November 19, 2024). With Kristel's healthcare background, she provides data driven actionable strategies to leverage happiness and high-power habits to drive growth mindsets, peak performance, profitability, well-being and a culture of excellence. Kristel's keynotes provide insights to "Live Greatly" while promoting leadership development and team building.   Kristel is the creator and host of her global top self-improvement podcast, Live Greatly. She is a contributing writer for Entrepreneur, and she is an influencer in the business and wellness space having been recognized as a Top 10 Social Media Influencer of 2021 in Forbes. As an Integrative Medicine Fellow & Physician Assistant having practiced clinically in Integrative Psychiatry, Kristel has a unique perspective into attaining a mindset for more happiness and success. Kristel has presented to groups from the American Gas Association, Bank of America, bp, Commercial Metals Company, General Mills, Northwestern University, Santander Bank and many more. Kristel has been featured in Forbes, Forest & Bluff Magazine, Authority Magazine & Podcast Magazine and she has appeared on ABC 7 Chicago, WGN Daytime Chicago, Fox 4's WDAF-TV's Great Day KC, and Ticker News. Kristel lives in the Fort Lauderdale, Florida area and she can be booked for speaking engagements worldwide. To Book Kristel as a speaker for your next event, click here. Website: www.livegreatly.co  Follow Kristel Bauer on: Instagram: @livegreatly_co  LinkedIn: Kristel Bauer Twitter: @livegreatly_co Facebook: @livegreatly.co Youtube: Live Greatly, Kristel Bauer To Watch Kristel Bauer's TEDx talk of Redefining Work/Life Balance in a COVID-19 World click here. Click HERE to check out Kristel's corporate wellness and leadership blog Click HERE to check out Kristel's Travel and Wellness Blog Disclaimer: The contents of this podcast are intended for informational and educational purposes only. Always seek the guidance of your physician for any recommendations specific to you or for any questions regarding your specific health, your sleep patterns changes to diet and exercise, or any medical conditions.  Always consult your physician before starting any supplements or new lifestyle programs. All information, views and statements shared on the Live Greatly podcast are purely the opinions of the authors, and are not medical advice or treatment recommendations.  They have not been evaluated by the food and drug administration.  Opinions of guests are their own and Kristel Bauer & this podcast does not endorse or accept responsibility for statements made by guests.  Neither Kristel Bauer nor this podcast takes responsibility for possible health consequences of a person or persons following the information in this educational content.  Always consult your physician for recommendations specific to you.

The battle between Novo Nordisk and Pfizer to acquire Metsera is over. But is this merger a sign of strength or weakness for the industry? Today on the show, Rob Armstrong talks with US finance editor James Fontanella-Khan about the pressures on drug companies from Washington and the market. Also they go long Nasdaq and short Nasdaq. For a free 30-day trial to the Unhedged newsletter go to: https://www.ft.com/unhedgedoffer.You can email Robert Armstrong and Katie Martin at unhedged@ft.com.Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Send us a text Trump and the Epstein files, Dems cave and reopen the government, Portland PD use of AI, Texas and Washington state allowing legal fights, Pfizer raking in profits for no cures, and in our GREAT DEBATERS we debate which Teen Titan would you fight? And a bit of NBA too! Support the show

Inside the Biggest M&A Deals You Need to Know (Pfizer, LVMH, Atlético Madrid, Parker Hannifin)In this week's M&A episode of AmplifyME Market Maker, Anthony and Piers break down the biggest deal headlines from Apollo taking control of Atlético Madrid to LVMH's stake in Swiss movement maker Le Joux-Perret, Parker Hannifin's $9.25 billion filtration acquisition, and Burger King's China JV. The deep dive focuses on Pfizer's $10 billion battle with Novo Nordisk for Metsera, unpacking the bidding war, regulatory tensions, the strategic race for obesity drugs, and why contingent value rights (CVRs) make this deal so unusual.(00:00) Atlético Madrid, LVMH & Parker Hannifin(03:55) Pfizer vs Novo Nordisk for Metsera(05:10) How the Bidding War Escalated to $10B(12:27) Contingent Value Right(18:10) Key Deal Takeaways*****Take part in a free M&A Finance Accelerator simulation

Are multivitamins bad for you? How could that be? In this video, I'll share the truth about the multivitamin scam. Find out about the vitamins you should never take, supplements that don't work, and the harmful ingredients in your supplements. 0:00 Introduction: Multivitamins truth0:19 Harmful ingredients in supplements 1:45 Synthetic vs. natural vitamins 3:38 Do multivitamins really work?9:32 Natural vitamins and minerals11:17 Fake vitamins exposed! Many multivitamins are made with the cheapest, synthetic ingredients which could be doing more harm than good.The first ingredient in many multivitamins is often calcium carbonate, which is limestone! The first ingredient usually makes up the majority of the product. Magnesium oxide, another common ingredient, is very cheap and has the lowest absorption rate compared to other forms of magnesium. The term “natural” isn't regulated, so ingredients derived from sources such as petroleum and coal tar can be labeled as natural. In nature, vitamins don't exist alone; they are combined with other nutrients and cofactors, which are often missing when you take synthetic vitamins. Biochemistry can not work without cofactors. Although there are nutrients that are difficult to obtain in sufficient amounts from food, that doesn't mean they should be replaced with synthetic multivitamins.Maltodextrin is commonly used as a filler in vitamins and minerals. It's a highly refined industrial starch, classified as a complex carbohydrate, and spikes blood sugar more than sugar. Ascorbic acid is a synthetic part of the vitamin C complex. Approximately 90% is made in China from GMO corn and sulfuric acid. Many people have a genetic issue converting cyanocobalamin, a synthetic form of B12, and folic acid, a synthetic form of B9, into their active forms. This can cause negative side effects in 40% of the population.Almost all of the popular multivitamins are owned by Big Pharma, Big Food, Big Chemical, or large investment groups. For example, Centrum Silver is owned by Pfizer, and One a Day is owned by Bayer. Nature Made is owned by the same company that sells Abilify!Dr. Eric Berg DC Bio:Dr. Berg, age 60, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the Director of Dr. Berg Nutritionals and author of the best-selling book The Healthy Keto Plan. He no longer practices, but focuses on health education through social media.Disclaimer: Dr. Eric Berg received his Doctor of Chiropractic degree from Palmer College of Chiropractic in 1988. His use of “doctor” or “Dr.” in relation to himself solely refers to that degree. Dr. Berg is a licensed chiropractor in Virginia, California, and Louisiana, but he no longer practices chiropractic in any state and does not see patients, so he can focus on educating people as a full-time activity, yet he maintains an active license. This video is for general informational purposes only. It should not be used to self-diagnose, and it is not a substitute for a medical exam, cure, treatment, diagnosis, prescription, or recommendation. It does not create a doctor-patient relationship between Dr. Berg and you. You should not make any change in your health regimen or diet before first consulting a physician and obtaining a medical exam, diagnosis, and recommendation. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition.

¡Emprendeduros! En este episodio Rodrigo nos da una actualización de mercado donde habla del estatus del mercado, de los anuncios de la Casa Blanca y del fin al cierre del gobierno. Nos da los reportes de ingresos de CoreWeave, Occidental Petroleum, Tyson Foods, On Holdings, Oklo y Disney. Después habla de la adquisicion de Pfizer y de los nuevos terminos de hipotecas y prestamos de autos. Finalmente contestara unas preguntas de los Emprendeduros. Unete al grupo de inversión: https://www.youtube.com/channel/UCy5-O9CmBVndvL6Kz_BP3-w/join ¡Síguenos en Instagram! Rodrigo: https://www.instagram.com/rodnavarro Emprendeduros: https://www.instagram.com/losemprendeduros Escucha mi Audiolibro: De Novato a Inversionista - El ABC de la Bolsa de Valores https://bit.ly/NovatoInversionista Para mas información sobre nuestro fondo visita: https://emprendedurosventures.com/

Jason Feifer discusses how to advance your career by creating winning LinkedIn content. — YOU'LL LEARN — 1) Why LinkedIn matters even when you aren't job hunting2) What most get wrong about personal branding 3) The trick to getting your posts seen on LinkedInSubscribe or visit AwesomeAtYourJob.com/ep1110 for clickable versions of the links below. — ABOUT JASON — Jason Feifer is the editor in chief of Entrepreneur magazine, a startup advisor, host of the podcasts Build For Tomorrow and Problem Solvers, and has taught his techniques for adapting to change at companies including Pfizer, Microsoft, Chipotle, DraftKings, and Wix. He has worked as an editor at Fast Company, Men's Health, and Boston magazine, and has written about business and technology for the Washington Post, Slate, Popular Mechanics, and others.• LinkedIn: Jason Feifer• Newsletter: OneThingBetter.email• Website: JasonFeifer.com— RESOURCES MENTIONED IN THE SHOW — • Book: The Three-Body Problem (The Three-Body Problem Series, 1) by Cixin Liu• Past episode: 664: Dr. Robert Cialdini on How to Persuade with the 7 Universal Principles of Influence• Past episode: 848: How to Quickly Grow and Future-Proof Your Career with Jason Feifer• Past episode: 997: How to Push Past Self-Doubt and Find the Confidence to Pursue Big Things with Pat Flynn and Matt Gartland• Past episode: 1089: Mastering New Skills and Information Overload through Lean Learning with Pat Flynn— THANK YOU SPONSORS! — • Vanguard. Give your clients consistent results year in and year out with vanguard.com/AUDIO• Quince. Get free shipping and 365-day returns on your order with Quince.com/Awesome• Cashflow Podcasting. Explore launching (or outsourcing) your podcast with a free 10-minute call with Pete.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We discuss Pfizer's $10 billion deal to buy Metsera and finally get into weight loss. Plus, Peloton is making a compeback and Circle is growing on the back of stablecoins, but Coinbase may be the real winner here. Travis Hoium, Rachel Warren, and Jon Quast discuss: - Pfizer buying Metsera - Peloton's comeback - Circle's growth and why Coinbase is a winner Companies discussed: Pfizer (PFE), Peloton (PTON), Circle (CRCL), Coinbase (COIN). Host: Travis Hoium Guests: Rachel Warren, Jon Quast Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

Angel Studios https://Angel.com/HermanJoin the Angel Guild today and know you are not just watching, you're helping make bold, faith driven stories like Disciples in the Moonlight possible. That's Angel.com/HermanRenue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comRegister now for the free Review/Preview Webinar November 20th 3:30pm Pacific, schedule your free Know Your Risk Portfolio Review, and subscribe to Zach's Daily Market Recap at (SLOW) Know Your Risk Podcast dot com. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/toddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.Ben Shapiro has become a hall monitor, per se. There are certain things you can't talk about. You cannot question the government of Israel around Ben Shapiro, and up until very recently, you couldn't ask questions about the mRNA injections.Episode Links:Mark Levin reads private text messages with Tucker Carlson revealing that TPUSA wanted the two men to debate. Carlson said he was open to debate but Levin refused because he didn't want to “platform” Carlson. Levin then bragged about his “rational” response where he called Carlson “the modern-day David Duke.” What a bizarre response.“I don't want to have a war with Ben Shapiro...” @TuckerCarlson on whether he and Ben Shapiro can find a way to detente.Qatar sent millions to Gaza for years – with Israel's backing. Here's what we know about the controversial dealFormer Capitol Police officer a forensic match for Jan. 6 pipe bomber, sources sayBen Shapiro admitting we were lied to by everyone including Pfizer, the government & the scientists compiled with new clips of him shaming people for asking question

Prescription drugs in the U.S. cost nearly three times more than in other developed countries, driving financial strain for millions of Americans and fueling demand for reform TrumpRx, a new government-run website set to launch in 2026, will let Americans buy discounted medications directly from drug manufacturers, bypassing insurers and pharmacy benefit managers Pfizer is the first major pharmaceutical partner, pledging to sell many drugs at up to 50% off list prices, match global "Most Favored Nation" pricing, and invest $70 billion in U.S. manufacturing The TrumpRx initiative stems from President Trump's May 2025 executive order reinstating "Most Favored Nation" pricing, which requires drugmakers to charge Americans no more than patients in other wealthy nations TrumpRx also includes plans to cut U.S. prescription spending by half, reinvest $500 billion into domestic production, and give financially struggling Americans direct access to low-cost or even free medications

4. When Politicians Panicked: The New Coronavirus, Expert Opinion, and a Tragic Lapse of Reason. The discussion critiques the indiscriminate government funding of the Payroll Protection Program (PPP), which subsidized well-endowed institutions and missed future innovators, thereby slowing the natural process of working out what is "good and what's bad." Government lending programs inevitably come with strings attached and impair credit. John Tamny suggests that individuals possess a protected "right to contract" and work, regardless of state mandates, citing Lochner v. New York. Ultimately, the sources stress that economic growth and freedom are the strongest defenses against disease, highlighted by the rapid success of private enterprise (like Pfizer) in vaccine development. Freedom must be the readymade answer to future pandemics. 1918 Retry

Pfizer faces over a thousand lawsuits from women after its popular birth control drug, Depo-Provera, was linked to brain tumors. As the UN releases a report on the global fertility crisis, Illinois Governor J.B. Pritzker is moving to allow pharmacists to dispense birth control without a doctor's prescription.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

Bonus Episode for Nov. 4. The weight-loss-drug arms race is only heating up, as Novo Nordisk attempts to snatch drugmaker Metsera away from Pfizer. But can either company compete with Zepbound seller Eli Lilly? WSJ reporter Peter Loftus discusses what earnings from Big Pharma, including AbbVie, Bristol Myers Squibb and Merck, say about the future of the industry and how companies are responding to President Trump's drug-pricing plans, including TrumpRx. WSJ Heard on the Street columnist David Wainer hosts this special bonus episode of What's News in Earnings, where we dig into companies' earnings reports and analyst calls to find out what's going on under the hood of the American economy. Sign up for the WSJ's free Markets A.M. newsletter. Further Reading: Novo Nordisk Sweetens Offer for Metsera - WSJ Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk The Day Pharma's Weight-Loss Gold Rush Intensified Pfizer Profit Falls Amid Lower Covid-19 Drug Demand Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera Novo Nordisk to Shake Up Board After Obesity-Market Challenges Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings AbbVie Lifts Profit Outlook as Sales Rise Bristol Myers Squibb Profit Soars, Raises Revenue Guidance Merck Profit Rises on Strong Keytruda Demand GSK Lifts Guidance After Specialty Medicines Boost Sales Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains Learn more about your ad choices. Visit megaphone.fm/adchoices